96 Results for "

motor function

" in MedChemExpress (MCE) Product Catalog:
Products (96)

96 Results for "motor function" in MCE Product Catalog:

Cat. No.: HY-186215
CAS No.: 1689545-27-4
Target:  

TRP Channel

Research Areas:  

Infection

Indazapyroxamet is an orally active insect TRPV channel (Nan/Iav subunit) modulator and insecticide. Indazapyroxamet antagonizes nicotinamide-induced calcium influx, inhibits insect motor function, and impairs negative geotaxis in wild-type Drosophila melanogaster via functional TRPV channels .
loading...
    loading...
Cat. No.: HY-P11780
CAS No.: 208116-26-1
Target:  

Integrin MMP

Research Areas:  

Neurological Disease Cancer

KAFDITYVRLKF is a selective, competitive integrin αvβ3 binder. KAFDITYVRLKF induces the production of MMP-9. KAFDITYVRLKF blocks monocyte migration, promotes melanoma cell migration, protects neurons, and improves motor and cognitive functions. KAFDITYVRLKF can be used in research related to melanoma and Parkinson's disease .
loading...
    loading...
Cat. No.: HY-187892
CAS No.: 3060541-19-4
Synonyms: ATH-1105
Brelgometon (ATH-1105) is an orally active HGF/MET positive modulator . Brelgometon activates downstream ERK and AKT cascades. Brelgometon reduces pro-inflammatory cytokine levels and extranuclear TDP-43 aggregation; it also upregulates EAAT2 expression and improves mitochondrial function. Brelgometon protects neurons from excitotoxicity, inflammation, oxidative stress and mitochondrial dysfunction; it also maintains neurite length, neuromuscular junction integrity and sciatic nerve function. Brelgometon alleviates motor function deterioration, maintains body weight and prolongs survival in ALS transgenic mice. Brelgometon is applicable to research related to amyotrophic lateral sclerosis .
loading...
    loading...
Cat. No.: HY-17417B
CAS No.: 51481-60-8
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

Naloxone hydrochloride is an orally active opioid receptor antagonist. Naloxone hydrochloride attenuates spinal cord stimulation‑associated anti‑hyperalgesic effects, antagonizes physiologic effects of endogenous opioid peptides linked to central nervous system injury sequelae, functions as a pressor agent to induce modest elevations in mean arterial blood pressure, exerts neuroprotective effects to improve post‑traumatic neurologic motor function, blocks opioid receptor‑mediated amnesic pathways, enhances memory consolidation, reverses Adrenocorticotropic hormone (ACTH) (HY-106373)‑ and epinephrine‑induced amnesia, and potentiates the memory‑facilitatory effects of ACTH and epinephrine .
loading...
    loading...
Cat. No.: HY-181549
CAS No.: 3080627-61-5
PDE4-IN-32 (Compound B05) is a selective, blood-brain barrier permeable PDE4B and PDE4D inhibitor with IC50 values of 13.7 nM and 23.8 nM, respectively. PDE4-IN-32 promotes the recovery of motor and cognitive function in MCAO/R mouse models. PDE4-IN-32 reduces cerebral edema. PDE4-IN-32 can be used for the research of ischemic stroke .
loading...
    loading...
Cat. No.: HY-181897
CAS No.: 1903786-86-6
mHTT ligand-1 is an mHTT ligand. As a Ligand for Target Protein for PROTAC, mHTT ligand-1 can be used to develop and design PROTAC-based mHTT degraders, such as PROTAC mHTT Degrader-1 (HY-181879). mHTT ligand-1 is applicable to research related to Huntington's disease .
loading...
    loading...
Cat. No.: HY-184381
Target:  

Monoamine Oxidase

Research Areas:  

Neurological Disease

MAO-B-IN-61 is an orally active, brain-penetrant, highly selective, mixed-type reversible MAO-B inhibitor (IC50 = 14 nM, SI for MAO-A > 2857). MAO-B-IN-61 exhibits no significant cytotoxicity across various human cell lines and demonstrates good metabolic stability in rat and human liver microsomes. In an MPTP (HY-W114750)-induced rat model of Parkinson's disease, MAO-B-IN-61 exhibits significantly improving motor function and positioning itself as a promising candidate for Parkinson's disease research .
loading...
    loading...
Cat. No.: HY-186316
CAS No.: 2769053-56-5
KDS12025 is a blood-brain barrier-permeable, orally active H2O2-decomposing peroxidase enhancer. KDS12025 enhances the H2O2-decomposing pseudoperoxidase activity of Hb without altering oxygen transport function, and reduces intracellular H2O2 load. KDS12025 reduces abnormal H2O2 levels and inhibits the production of COL1. KDS12025 restores cerebral blood flow, maintains neuronal excitability, membrane properties, synaptic connections and corticospinal tract fibers, reduces cerebral edema and exerts neuroprotective effects. KDS12025 improves motor function and overall neurological function. KDS12025 can be used in the research of ischemic stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, aging-related neurodegenerative diseases and rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-108942
CAS No.: 851087-60-0
ASP5854 is an orally active, blood-brain barrier permeable adenosine A1/A2a dual receptor antagonist. ASP5854 blocks receptor activity and agonist-induced intracellular calcium elevation, and exhibits the characteristic of slow dissociation from striatal A2a receptors in primates. ASP5854 reverses catalepsy, enhances cognitive ability, improves motor function and exerts neuroprotective effects, while also alleviating dyskinesia and increasing contralateral turning behavior. ASP5854 is mainly used in studies related to ischemic stroke and Parkinson's disease .
loading...
    loading...
Cat. No.: HY-187700
Research Areas:  

Neurological Disease

BRD3290 is a GluA3-preferring AMPA receptor positive allosteric modulator with brain exposure in Mus musculus (mice) following peripheral administration. BRD3290 preferentially potentiates GluA3-containing AMPA receptors over GluA1/2-containing AMPA receptors. BRD3290 increases cerebellar cGMP levels in Mus musculus (mice). BRD3290 does not induce convulsions, alter motor function, or improve novel object recognition task performance in Mus musculus (mice) at tested doses. BRD3290 can be used for the research of schizophrenia .
loading...
    loading...
Cat. No.: HY-114118C
CAS No.: 2924330-56-1
Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
Cat. No.: HY-111751R
CAS No.: 2035814-50-5
Research Areas:  

Neurological Disease

JNJ-61432059 (Standard) is the analytical standard of JNJ-61432059 (HY-111751). This product is intended for research and analytical applications. JNJ-61432059 is a blood-brain barrier-permeable, orally active TARP γ-8-associated AMPAR modulator with anticonvulsant activity. JNJ-61432059 negatively regulates GluA1 and positively modulates GluA2-containing AMPARs. JNJ-61432059 exerts potent protective effects in rodent epilepsy models without impairing motor function. JNJ-61432059 is applicable for epilepsy-related research .
loading...
    loading...
Cat. No.: HY-182893
CAS No.: 1919889-97-6
SK-129 is a blood-brain barrier-permeable inhibitor of α-synuclein (αS) oligomers with a Kd of 221 nM. SK-129 preferentially binds to neurotoxic αS oligomers over physiological αS monomers, inhibits αS aggregation, blocks the interaction and co-aggregation of αS with tau protein, and prevents the maturation of αS-tau condensates into amyloid aggregates. SK-129 reduces ROS production, rescues dopaminergic neuron degeneration, improves motor function, restores endogenous dopamine synthesis, increases the number of Tyrosine Hydroxylase-positive neurons, prevents brain histopathological changes, alleviates neuroinflammation, and improves survival rates in relevant models. SK-129 can be used in research related to Parkinson's disease (PD) and Lewy body dementia (LBD) .
loading...
    loading...
Cat. No.: HY-L165
282 compounds

Dopamine receptor (DAR), widely distributed in the brain, plays a key role in regulating motor function, motivation, driving force and cognition. The role of DA is mediated by D1-type (D1, D5) and D2-type receptors (D2S, D2L, D3, D4), which are distributed in presynaptic, postsynaptic and extrasynaptic, projection neurons and interneurons. Each receptor has a different function. D1 and D5 receptors couple with G stimulation sites and activate Adenylyl cyclase. The activation of Adenylyl cyclase leads to the production of the second messenger cAMP, which leads to the production of protein kinase A (PKA), which leads to further transcription in the nucleus. D2 to D4 receptors are coupled to G inhibitory sites to inhibit adenylyl cyclase and activate potassium Ion channel. These receptors utilize phosphorylation cascades or direct membrane interactions to affect the functions of voltage-gated and neurotransmitter-gated channels, cytoplasmic enzymes, and transcription factors. Dopamine receptor plays an important role in daily life.

MCE designs a unique collection of 282 small molecules related to dopamine receptor. It is a good tool for screening drugs from nervous system disease.

Cat. No.: HY-P12141
CAS No.: 2227651-65-0
Synonyms: KP405
DA5-CH (KP405) is a blood-brain barrier-permeable GLP-1/GIP receptor agonist. DA5-CH activates GLP-1 and GIP receptors, inhibits the NF-κB inflammatory pathway, reduces α-synuclein (α-synuclein) levels, restores the expression of tyrosine hydroxylase and neurotrophic factors, improves motor function, decreases amyloid plaques and phosphorylated tau protein levels in the hippocampus, restores synaptic plasticity, regulates the PI3K/AKT/GSK3β and CREB signaling pathways, and alleviates mitochondrial stress. DA5-CH can be used for research on Parkinson's disease and Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-W010178R
CAS No.: 54947-74-9
4-Methyloctanoic acid (Standard) is the analytical standard of 4-Methyloctanoic acid (HY-W010178). This product is intended for research and analytical applications. 4-Methyloctanoic acid is an endogenous branched-chain medium-chain fatty acid and a negative regulator of the cAMP/PKA signaling pathway. 4-Methyloctanoic acid exerts antiepileptic effects by inhibiting epileptiform discharges and terminating behavioral and electroencephalographic seizures. 4-Methyloctanoic acid has neuroprotective effects; its polar metabolites can cross the blood-brain barrier, repair presynaptic release defects, improve motor function and alleviate neuromuscular degeneration in ALS models. 4-Methyloctanoic acid regulates phosphatidylinositol metabolism, reduces PIP/PIP2 levels and increases inositol levels. 4-Methyloctanoic acid can be used in studies related to epilepsy and amyotrophic lateral sclerosis .
loading...
    loading...